This NDC is on FDA's drug shortage list (posted Jul 26, 2023)
Reported reason: Demand increase for the drug
Product Information
METHYLPHENIDATE ER 54 MG TAB is a generic product labeled by Trigen Laboratories, LLC, priced at $0.8051 per EA under NDC 13811070910. Its NADAC has been published 472 times since Sep 20, 2017.
FDA first approved this application on Jul 28, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
54 mg/1
Manufacturer
Trigen Laboratories, LLCNDC
13811070910
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METHYLPHENIDATE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA205327FDA Approved
7/28/2017
TE Code
AB
On Market Since
8/14/2017
Pharmacological Classes
Price Statistics
The NADAC for METHYLPHENIDATE ER 54 MG TAB has been published 472 times since Sep 20, 2017, and over the history we have for it it has declined 90.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8051 per EA |
|---|---|
| All-time high | $8.5288 (Apr 11, 2018) |
| All-time low | $0.6051 (Feb 22, 2023) |
| 52-week high | $0.8447 |
| 52-week low | $0.7632 |
| Median price | $1.0444 |
| Average price | $2.8289 |
| Largest weekly change | +71.1% (Nov 22, 2023) |
| Weeks tracked | 472 |
| Tracking since | Sep 20, 2017 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Trigen Laboratories, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Methylphenidate hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METHYLPHENIDATE ER 54 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for METHYLPHENIDATE ER 54 MG TAB, manufactured by Trigen Laboratories, LLC, is $0.8051 per EA (NDC 13811070910), effective Sep 30, 2026.
How has the price of METHYLPHENIDATE ER 54 MG TAB changed over time?
Over the history we have for it, the NADAC for METHYLPHENIDATE ER 54 MG TAB has declined 90.4%. It has been tracked across 472 weekly CMS publications since Sep 20, 2017.
What are the highest and lowest recorded NADAC prices for METHYLPHENIDATE ER 54 MG TAB?
Since Sep 20, 2017, the NADAC for METHYLPHENIDATE ER 54 MG TAB has ranged from a low of $0.6051 (Feb 22, 2023) to a high of $8.5288 (Apr 11, 2018), with a median of $1.0444 per EA.
Are there cheaper alternatives to METHYLPHENIDATE ER 54 MG TAB?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as METHYLPHENIDATE ER 54 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures METHYLPHENIDATE ER 54 MG TAB?
METHYLPHENIDATE ER 54 MG TAB (NDC 13811070910) is labeled by Trigen Laboratories, LLC, and CMS classifies it as a generic product.
Is METHYLPHENIDATE ER 54 MG TAB in shortage?
Yes — NDC 13811070910 is currently listed in FDA's drug shortage database (posted Jul 26, 2023). Reported reason: Demand increase for the drug.